\n
\u00a0<\/strong><\/p>\n Ain Alalam – Rashad Iskandrni<\/strong><\/p>\n July 16 2026 <\/strong>\u2013 Abbott, a global healthcare leader, announced the launch of its latest generation of continuous glucose monitoring (CGM) technology, FreeStyle Libre 3 Plus*, in the Kingdom of Saudi Arabia.<\/p>\n \n The launch comes at a critical time as Saudi Arabia continues to face one of the world\u2019s highest diabetes prevalence rates, with more than 5 million adults \u2013 nearly 1 in 4 \u2013 living with the condition[1]<\/a>. Libre CGM systems help people living with diabetes better understand how different foods, exercise and medications[2]<\/a> impact their glucose levels in real time, enabling them to make more informed decisions[3]<\/a> on how they can manage their diabetes on their own terms.<\/p>\n \n Designed to make glucose monitoring simpler and more user-friendly[4]<\/a>, FreeStyle Libre 3 Plus* empowers individuals to take an active role in living with their condition, increasing confidence[5]<\/a>\u00a0and driving better health outcomes[6]<\/a>,[7]<\/a>,[8]<\/a>.<\/p>\n The FreeStyle Libre 3 Plus sensor is Abbott\u2019s smallest sensor to date\u2021, developed with user\u2019s everyday needs in mind. The sensor is discreet, easy\u2011to\u2011apply, and offers an extended wear of up to 15 days \u2014 requiring only six sensors every three months \u2014 while providing outstanding accuracy[9]<\/a> with real-time glucose readings sent directly to FreeStyle Libre 3 users\u2019 smartphone app#.<\/p>\n \n The system is approved for all people with diabetes aged 2 and older, including pregnant women, reinforcing Abbott\u2019s commitment to helping people access the care they need and live healthier, fuller lives.<\/p>\n \n “As the global leader in CGM, Abbott continues to advance the standard of diabetes care and make it easier for people to manage their condition,” said Mohammad Househ, general manager of Abbott\u2019s diabetes care business in Saudi Arabia, Bahrain, the Middle East and Northern Africa. “We are proud to introduce in Saudi Arabia FreeStyle Libre 3 Plus*, our most compact and user-friendly sensor yet, offering transformative benefits to help people living with diabetes take actions that can add up to big changes over time.”<\/p>\n \n To learn more about Abbott\u2019s FreeStyle Libre 3 Plus* sensor, visit FreeStyle.abbott\/sa<\/a><\/p>\n Figure 1 ABBOTT\u2019S LATEST GENERATION FREESTYLE LIBRE 3 PLUS LAUNCHES IN SAUDI ARABIA<\/p>\n \n About FreeStyle Libre<\/strong>:<\/strong><\/p>\n Abbott continues to pioneer ground-breaking technology to support people living with diabetes. The company revolutionized diabetes care more than 10 years ago with its world-leading FreeStyle Libre continuous glucose monitoring portfolio, which today is used by more than 8 million people across over 60 countries. People use Libre technology to see their glucose numbers in real-time, providing insights into how food, activity, or insulin impacts their glucose[10]<\/a> to help them make progress on their health goals. There is full or partial reimbursement for Libre systems in more than 40 countries.[11]<\/a><\/p>\n \u00a0<\/strong><\/p>\n About Abbott:<\/strong><\/p>\n Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.<\/p>\n \n Connect with us at\u00a0www.arabia.abbott\u00a0and on\u00a0LinkedIn<\/a>,\u00a0Facebook<\/a>,\u00a0Instagram<\/a>,\u00a0X<\/a>, and\u00a0YouTube<\/a>.<\/p>\n [1]<\/a> \u00a0Diabetes in Saudi Arabia (2024), International Diabetes Federation<\/p>\n [2]<\/a> Continuous Glucose Monitoring – NIDDK.\u201d National Institute of Diabetes and Digestive and Kidney Diseases. Accessed June 23, 2025. https:\/\/www.niddk.nih.gov\/health-information\/diabetes\/overview\/managing-diabetes\/continuous-glucose-monitoring.<\/p>\n [3]<\/a> Fokkert, M. BMJ Open Diabetes Research & Care (2019). https:\/\/doi.org\/10.1136\/bmjdrc-2019-000809.<\/p>\n [4]<\/a> Haak, T. Diabetes Therapy (2017): https:\/\/doi.org\/10.1007\/s13300-016-0223-6<\/p>\n [5]<\/a> Fokkert M. BMJ Open Diab Res Care (2019): http:\/\/dx.doi.org\/10.1136\/bmjdrc-2019-000809<\/p>\n [6]<\/a> Bolinder, J. Lancet (2016): https:\/\/doi.org\/10.1016\/S0140-6736(16)31535-5<\/p>\n [7]<\/a> Yaron, M. Diabetes Care (2019): https:\/\/doi.org\/10.2337\/dc18-0166<\/p>\n [8]<\/a> Haak, T. Diabetes Therapy (2017): https:\/\/doi.org\/10.1007\/s13300-016-0223-6<\/p>\n [9]<\/a> Accuracy of a 15-day Factory-Calibrated Continuous Glucose Monitoring System With Improved Sensor Design. Journal of Diabetes Science and Technology (2025) DOI: 10.1177\/19322968251329364<\/p>\n journals.sagepub.com\/home\/dst<\/p>\n